Application of vaccine technology to prevention of Pseudomonas aeruginosa infections

Expert Review of Vaccines

Volumn 4, Issue 5, 2005, Pages 645-656

  Pier, Gerald ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alginare; Conjugation; Cystic fibrosis; Pseudomonas aeruginosa; Vaccine; Ventilator associated pneumonia

Indexed keywords

ALGINIC ACID; ANTIGEN; CARBOHYDRATE ANTIGEN; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDE; LIVE VACCINE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; OPSONIN; PROTEINASE; PSEUDOMONAS VACCINE; RECOMBINANT ANTIGEN; TOXIN;

ACTIVE IMMUNIZATION; ADDITION REACTION; ANTIGEN EXPRESSION; ANTIGEN PURIFICATION; CELLULAR IMMUNITY; CONTACT LENS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; FLAGELLUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; KERATITIS; LUNG INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; TISSUE REACTION; TREATMENT OUTCOME;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNIZATION, PASSIVE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VACCINATION; VACCINES, ATTENUATED; VACCINES, CONJUGATE;

EID: 27444434285     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.5.645     Document Type: Review

References (127)

1. Hatano K, Pier GB. Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains. Infect. Immun. 66(8), 3719-3726 (1998).
2. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15(2), 194-222 (2002).
3. Hemachandra S, Kamboj K, Copfer J, Pier G, Green LL, Schreiber JR. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis. Infect. Immun. 69(4), 2223-2229 (2001).
4. Markham RB, Pier GB, Schreiber JR. The role of cytophilic IgG 3 antibody in T-cell-mediated resistance to infection with the extracellular bacterium Pseudomonas aeruginosa. J. Immunol. 146(1), 316-320 (1991).
5. Dunkley ML, Clancy RL, Cripps AW. A role for CD4(+) T-cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. Immunology 83(3), 362-369 (1994).
6. Dunkley ML, Cripps AW, Clancy RL. Immunity to respiratory Pseudomonas aeruginosa infection: P. aeruginosa-specific T-cells arising after intestinal immunization. Adv. Exp. Med. Biol. 755-759 (1995).
7. Dunkley ML, Cripps AW, Reinbott PW, Clancy RL. Immunity to respiratory Pseudomonas aeruginosa infection: the role of gut-derived T-helper cells and immune serum. Adv. Exp. Med. Biol. 771-775 (1995).
8. Frank DW, Vallis A, Wiener-Kronish JP et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J. Infect. Dis. 186(1), 64-73 (2002). Demonstrates the potential for immunotherapy directed towards the PcrV antigen in the Type III secretion complex.
9. Schreiber JR, Cooper LJN, Diehn S et al. Variable region-identical monoclonal antibodies of different IgG subclass directed to Pseudomonas aeruginosa lipopolysaccharide O-specific side chain function differently. J. Infect. Dis. 167(1), 221-226 (1993).
10. Hancock REW, Mutharia LM, Chan L, Darveau RP, Speert DP, Pier GB. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect. Immun. 42, 170-177 (1983).
11. Schiller NL. Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains. Infect. Immun. 56, 632-639 (1988).
12. Pier GB, Thomas D, Small G, Siadak A, Zweerink H. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulin G, M and A against Pseudomonas aeruginosa lipopolysaccharide. Infect. Immun. 57, 174-179 (1989).
13. Pier GB, Koles NL, Meluleni G, Hatano K, Pollack M. Specificity and function of murine monoclonal antibodies and immunization induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup O6. Infect. Immun. 62(4), 1137-1143 (1994).
14. Pollack M, Koles NL, Preston MJ, Brown BJ, Pier GB. Functional properties of isotype-switched Immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide. Infect. Immun. 63(11), 4481-4488 (1995).
15. Preston MJ, Gerceker AA, Reff ME, Pier GB. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide. Infect. Immun. 66(9), 4137-4142 (1998).
16. Pitt PL, MacDougall J, Penketh ARL, Cooke EM. Polyagglutinating and non-typable strains of Pseudomonas aeruginosa in cystic fibrosis. J. Med. Microbiol. 21, 179-186 (1986).
17. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60(3), 539-574 (1996).
18. Jensen ET, Kharazmi A, Garred P et al. Complement activation by Pseudomonas aeruginosa biofilms. Microb. Pathog. 15(5), 377-388 (1993).
19. Jones RJ, Roe EA, Gupta JL. Low mortality in burned patients in a Pseudomonas vaccine trial. Lancet 2(8086), 401-403 (1978).
20. Jones RJ, Roe EA, Gupta JL. Controlled trials of a polyvalent Pseudomonas vaccine in burns. Lancet 2(8150), 977-982 (1979).
21. Jones RJ, Roe EA, Gupta JL. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients. Lancet 2(8207), 1263-1265 (1980).
22. Roe EA, Jones RJ. Immunization of burned patients against Pseudomonas aeruginosa infection at Safdarjang Hospital, New Delhi. Rev. Infect. Dis. 5, S922-S930 (1983).
23. Hatano K, Boisot S, Desjardins D, Wright DC, Brisker J, Pier GB. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. Infect. Immun. 62, 3608-3616 (1994).
24. Pier GB. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen. Carbohydr. Res. 338(23), 2549-2556 (2003).
25. Edelman R, Taylor DN, Wasserman SS et al. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine 12(14), 1288-1294 (1994).
26. Campbell WN, Hendrix E, Cryz S, Cross AS. Immunogenicity of a 24-valent klebsiella capsular polysaccharide vaccine and an eight-valent pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma. Clin. Infect. Dis. 23(1), 179-181 (1996).
27. Donta ST, Peduzzi P, Cross AS et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. J. Infect. Dis. 174(3), 537-543 (1996).
28. Montie TC, Drake D, Sellin H, Slater O, Edmonds S. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection. Antibiot. Chemother. 39, 233-248 (1987).
29. Rotering H, Dorner F. Studies on a Pseudomonas aeruginosa flagella vaccine. Antibiot. Chemother. 42, 218-228 (1989).
30. Gilleland HE Jr, Gilleland LB, Matthews-Greer JM. Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model. Infect. Immun. 56(5), 1017-1022 (1988).
31. Fox CW, Campbell GD, Anderson WM, Zavecz JH, Gilleland LB, Gilleland HE. Preservation of pulmonary function by an outer membrane protein F vaccine - A study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa. Chest 105(5), 1545-1550 (1994).
32. Mansouri E, Gabelsberger J, Knapp B, Hundt E et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 67(3), 1461-1470 (1999).
33. von Specht BU, Knapp B, Muth G et al. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins. Infect. Immun. 63(5), 1855-1862 (1995).
34. Knapp B, Hundt E, Lenz U et al. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine 17(13-14), 1663-1666 (1999).
35. Thomas LD, Kyd JM, Bastin DA, Dunkly ML, Cripps AW. Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 37(2-3), 155-160 (2003).
36. Sawa T, Yahr TL, Ohara M et al. Active and passive immunization with the Pseudomonas V antigen protects against Type III intoxication and lung injury. Nature Med. 5(4), 392-398 (1999).
37. Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect. Immun. 69(9), 5908-5910 (2001).
38. Sheth HB, Glasier LM, Ellert NW et al. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein. Biomed. Pept. Proteins Nucleic Acids 1(3), 141-148 (1995).
39. Yokota SI, Ohtsuka H, Noguchi H. Monoclonal antibodies against Pseudomonas aeruginosa elastase: a neutralizing antibody which recognizes a conformational epitope related to an active site of elastase. Eur. J. Biochem. 206(2), 587-593 (1992).
40. Gilleland HE, Gilleland LB, Fowler MR. Vaccine efficacies of elastase, exotoxin-A, and outer-membrane protein-F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model. J. Med. Microbiol. 38(2), 79-86 (1993).
41. Landsperger WJ, Kellywintenberg KD, Montie TC et al. Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat. Infect. Immun. 62(11), 4825-4830 (1994).
42. Lee N, Jung SB, Ahn BY et al. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy. Vaccine 18(18), 1952-1961 (2000).
43. Pier GB, Matthews WJ, Eardley DD. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. J. Infect. Dis. 147(3), 494-503 (1983).
44. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect. Immun. 67(9), 4744-4750 (1999).
45. Pier GB, Saunders JM, Ames P et al. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older, non-colonized cystic fibrosis patients. N. Engl. J. Med. 317, 793-798. (1987).
46. Pier GB, Small GJ, Warren HB. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infection. Science 249(4968), 537-540 (1990).
47. Meluleni GJ, Grout M, Evans DJ, Pier GB. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J. Immunol. 155(4), 2029-2038 (1995).
48. Pier GB, Boyer D, Preston M et al. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J. Immunol. 173(9), 5671-5678 (2004). Demonstrates that fully human monoclonal antibodies to alginate are opsonic and protective against pulmonary infection caused by both mucoid and nonmucoid strains.
49. Garner CV, Desjardins D, Pier GB. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide. Infect. Immun. 58, 1835-1842 (1990).
50. Pier GB, Desjardins D, Grout M et al. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect. Immun. 62, 3972-3979 (1994).
51. Fuller S, Propst M, Gross L et al. An immune globulin specific to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) promotes opsonic killing of isolates from cystic fibrosis (CF) patients. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. 23 (1994) (Abstract G7).
52. Tosi MF, Zakem-Cloud H, Demko CA et al. Cross sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody mediated protection and decline in opsonic quality after infection. J. Infect. Dis. 172(2), 453-461 (1995).
53. Pier GB, Grout M, Desjardins D. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins. J. Immunol. 147(6), 1869-1876 (1991).
54. Cryz SJ Jr, Purer E, Que JU. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin-A conjugate vaccine. Infect. Immun. 59(1), 45-50 (1991).
55. Theilacker C, Coleman F, Mueschenborn S, Grout M, Pier GB. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide/ alginate conjugate vaccine. Infect. Immun. 71(7), 3875-3884 (2003).
56. Schreiber JR, Pier GB, Grout M, Nixon K, Patawaran M. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody. J. Infect. Dis. 164(3), 507-514 (1991).
57. Pier GB, Coleman F, Grout M, Franklin M, Ohman DE. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis. Infect. Immun. 69(3), 1895-1901 (2001).
58. Fleiszig SM, Evans DJ. Contact lens infections: can they ever be eradicated? Eye Contact Lens 29(Suppl 1), S67-S71 (2003).
59. Fleiszig SM, Evans DJ. The pathogenesis of bacterial keratitis: studies with Pseudomonas aeruginosa. Clin. Exp. Optom. 85(5), 271-278 (2002). Good review of the components of Pseudomonas aeruginosa infection and host epithelial cell responses involved in pathogenesis of ulcerative keratitis.
60. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309-317 (2004).
61. Doring G, Dorner F. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring. Inst. Mitt. (98), 338-344 (1997).
62. Doring G, Pfeiffer C, Weber U, Mohrpennert A, Dorner F. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific antiflagella antibodies in the airways of healthy individuals. Amer. J. Respir. Crit. Care Med. 151(4), 983-985 (1995).
63. Wolfgang MC, Jyot J, Goodman AL, Ramphal R, Lory S. Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc. Natl Acad. Sci. USA 101(17), 6664-6668 (2004). Shows the importance of understanding antigenic expression in the context of tissue site of infection and its potential effects on vaccine development.
64. Price BM, Barten Legutki J, Galloway DR et al. Enhancement of the protective efficacy of an oprF DNA vaccine against Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 33(2), 89-99 (2002).
65. Gilleland HE Jr, Hughes EE, Gilleland LB, Matthews-Greer JM, Staczek J. Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of Pseudomonas aeruginosa. Curr. Microbiol. 31(5), 279-286 (1995).
66. Staczek J, Bendahmane M, Gilleland LB, Beachy RN, Gilleland HE. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa. Vaccine 18(21), 2266-2274 (2000).
67. Finke M, Duchene M, Eckhardt A, Domdey H, von Specht BU. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli. Infect. Immun. 58(7), 2241-2244 (1990).
68. von Specht BU, Strigl G, Ehret W, Brendel W. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection. Infection 15(5), 408-412 (1987).
69. Jang IJ, Kim IS, Park WJ et al. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine 17(2), 158-168 (1999).
70. Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect. Dis. Clin. North Am. 15(1), 155-169 (2001).
71. Sierra GV, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. Nature Inst. Public Health Ann. 14(2), 195-207 (1991).
72. Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338(8775), 1093-1096 (1991).
73. Hazes B, Sastry PA, Hayakawa K, Read RJ, Irvin RT. Crystal structure of Pseudomonas aeruginosa PAK pilin suggests a main-chain-dominated mode of receptor binding. J. Mol. Biol. 299(4), 1005-1017 (2000).
74. Keizer DW, Slupsky CM, Kalisiak M et al. Structure of a pilin monomer from Pseudomonas aeruginosa: implications for the assembly of pili. J. Biol. Chem. 276(26), 24186-24193 (2001).
75. Audette GF, Irvin RT, Hazes B. Purification, crystallization and preliminary diffraction studies of the Pseudomonas aeruginosa strain K122-4 monomeric pilin. Acta Crystallogr. D. Biol. Crystallogr. 59(Pt. 9), 1665-1667 (2003).
76. Irvin RT, Doig P, Lee KK et al. Characterization of the Pseudomonas aeruginosa pilus adhesin-confirmation that the pilin structural protein subunit contains a human epithelial cell-binding domain. Infect. Immun. 57(12), 3720-3726 (1989).
77. Wong WY, Campbell AP, McInnes C et al. Structure-function analysis of the adherence-binding domain on the pilin of Pseudomonas aeruginosa strains PAK and KB7. Biochemistry 34(40), 12963-12972 (1995).
78. Lee KK, Yu L, Macdonald DL, Paranchych W, Hodges RS, Irvin RT. Anti-adhesin antibodies that recognize a receptor-binding motif (adhesintope) inhibit pilus/fimbrial-mediated adherence of Pseudomonas aeruginosa and Candida albicans to asialo-GM1 receptors and human buccal epithelial cell surface receptors. Can. J. Microbiol. 42(5), 479-486 (1996).
79. Cachia PJ, Glasier LM, Hodgins RR, Wong WY, Irvin RT, Hodges RS. The use of synthetic peptides in the design of a consensus sequence vaccine for Pseudomonas aeruginosa. J. Pept. Res. 52(4), 289-299 (1998).
80. Pier GB. CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection. Curr. Opin. Microbiol. 5(1), 81-86 (2002).
81. Matsumoto T, Tateda K, Furuya N et al. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice. J. Med. Microbiol. 47(4), 303-308 (1998).
82. Shiau JW, Tang TK, Shih YL et al. Mice immunized with DNA encoding a modified Pseudomonas aeruginosa exotoxin A develop protective immunity against exotoxin intoxication. Vaccine 19(9-10), 1106-1112 (2000).
83. Sokol PA, Kooi C, Hodges RS, Cachia P, Woods DE. Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia. J. Infect. Dis. 181(5), 1682-1692 (2000).
84. Sheth HB, Lee KK, Wong WY et al. The pili of Pseudomonas aeruginosa strains PAK and PAO bind specifically to the carbohydrate sequence β GalNAc(1-4)β Gal found in glycosphingolipids asialo-GM1 and asialo-GM2. Mol. Microbiol. 11(4), 715-723 (1994).
85. Lakshman R, Finn A. Meningococcal serogroup C conjugate vaccine. Expert. Opin. Biol. Ther. 2(1), 87-96 (2002).
86. Makela PH. Conjugate vaccines - a breakthrough in vaccine development. Southeast Asian J. Trop. Med. Public Health 34(2), 249-253 (2003).
87. Pelton SI, Dagan R, Gaines BM et al. Pneumococcal conjugate vaccines: proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 21(15), 1562-1571 (2003).
88. Schaad UB, Lang AB, Wedgwood J et al. Safety and immunogenicity of Pseudomonas aeruginosa conjugate-A vaccine in cystic fibrosis. Lancet 338(8777), 1236-1237 (1991).
89. Cryz SJ Jr, Purer E, Sadoff JC, Fredeking T, Que JU, Cross AS. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J. Infect. Dis 163(5), 1055-1061 (1991).
90. Cryz SJ, Cross AS, Sadoff GC, Que JU. Human IgG and IgA subclass response following immunization with a polyvalent Klebsiella capsular polysaccharide vaccine. Eur J Immunol 18(12), 2073-2075 (1988).
91. Cryz SJ Jr, Sadoff JC, Purer E. Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans. Infect. Immun. 56, 1829-1830 (1988).
92. Cryz SJ Jr, Sadoff JC, Fürer E. Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Microb. Pathog. 6(1), 75-80 (1989).
93. Cryz SJ Jr, Lang A, Rudeberg A et al. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine. Behring Inst. Mitt. (98), 345-349 (1997).
94. Cryz SJ Jr, Wedgwood J, Lang AB et al. Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa. J. Infect. Dis. 169(5), 1159-1162 (1994).
95. Lang AB, Rudeberg A, Schoni MH, Que JU, Furer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr. Infect. Dis. J. 23(6), 504-510 (2004). Suggests possible efficacy of a lipopolysaccharide-specific vaccine in cystic fibrosis patients but does not represent results from a double-blind, placebo-controlled trial.
96. Johansen HK, Espersen F, Cryz SJ et al. Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection. Infect. Immun. 62(8), 3146-3155 (1994).
97. Johansen HK, Hougen HP, Cryz SJ, Rygaard J, Hoiby N. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia in rats. Amer. J. Respir. Crit. Care Med. 152(4), 1337-1346 (1995).
98. Pier GB, Markham RB. Serotypes and immune responses to Pseudomonas aeruginosa. In: Manual of Clinical Laboratory Immunology. Rose NR, Friedman H, Fahey JL (Eds). American Society for Microbiology, DC, USA, 399-491 (1986).
99. Anastassiou ED, Mintzas AS, Kounavis C, Dimitracopoulos G. Alginate production by clinical nonmucoid Pseudomonas aeruginosa. J. Clin. Microbiol. 25, 656-659 (1987).
100. Kyd JM, Cripps AW. Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview. Vaccine 17(13-14), 1775-1781 (1999).
101. Levine MM, Ferreccio C, Black RE, Germanier R; Committee at CT. Large-scale field trial of Ty21a live oral typhoid vaccine in enteic coated capsule formulation. Lancet 1, 1049-1052 (1987).
102. Barry EM, Altboum Z, Losonsky G, Levine MM. Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine 21(5-6), 333-340 (2003).
103. Kotloff KL, Taylor DN, Sztein MB et al. Phase I evaluation of δ-virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect. Immun. 70(4), 2016-2021 (2002).
104. Priebe GP, Brinig MM, Hatano K et al. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect. Immun. 70(3), 1507-1517 (2002).
105. Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB, Pier GB. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect. Immun. 71(3), 1453-1461 (2003).
106. Hooke AM, Cerquetti MC, Wan KS, Wang Z, Sordelli DO, Bellanti JA. Oral immunization of mice with temperature-sensitive Pseudomonas aeruginosa enhances pulmonary clearance of the wild type. Vaccine 9(5), 294-296 (1991).
107. Sordelli DO, Cerquetti MC, Hooke AM, Bellanti JA. Enhancement of Pseudomonas aeruginosa immunization with a temperature-sensitive mutant. Infect. Immun. 39(3), 1275-1279 (1983).
108. Arnold H, Bumann D, Felies M et al. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect. Immun. 72(11), 6546-6553 (2004).
109. DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect. Immun. 72(12), 7012-7021 (2004). Demonstrates the feasibility of expressing O sidechains of Pseudomonas aeruginosa in a heterologous antigen delivery system to yield opsonic and protective antibody.
110. Lang AB, Fürer E, Larrick JW, Cryz SJ Jr. Isolation and characterization of a human monoclonal antibody that recognizes epitopes shared by Pseudomonas aeruginosa immunotype 1, 3, 4, and 6 lipopolysaccharides. Infect. Immun. 47(12), 3851-3855 (1989).
111. Yokota S, Ochi H, Uezumi I, Ohtsuka H, Irie K, Noguchi H. N-acetyl-L-galactosaminouronic acid as an epitope common to the O-polysaccharides of Pseudomonas aeruginosa serotype A and H (Homma) recognized by a protective human monoclonal antibody. Eur. J. Biochem. 192(1), 109-113 (1990).
112. Terashima M, Uezumi I, Tomio T et al. A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide. Infect. Immun. 59(1), 1-6 (1991).
113. Yokota S, Ohtsuka H, Kohzuki T, Noguchi H. A polyreactive human antilipid A monoclonal antibody having cross-reactivity to polysaccharide portions of Pseudomonas aeruginosa lipopolysaccharides. FEMS Immunol. Med. Microbiol. 14(1), 31-38 (1996).
114. Harrison FJ, Rohm D, Kohzuki T, Noguchi H. Pharmacokinetics, tolerability, and preliminary efficacy of human anti Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients. Hybridoma 16(5), 413-420 (1997).
115. Meng YG, Wong T, Saravolatz LD, Pennington JE. Pharmacokinetics of an IgM human monoclonal antibody against Pseudomonas aeruginosa in nonseptic patients. J. Infect. Dis. 167(3), 784-785 (1993).
116. Lai Z, Kimmel R, Petersen S et al. Multivalent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal Pseudomonas sepsis caused by multiple serotypes. Vaccine 23(25), 3264-3271 (2005).
117. Matsumoto T, Tateda K, Miyazaki S et al. Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice. Clin. Diagn. Lab. Immunol. 6(4), 537-541 (1999).
118. Coleman FT, Mueschenborn S, Meluleni G et al. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc. Natl Acad. Sci. USA 100(4), 1949-1954 (2003).
119. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J. Clin. Epidemiol. 48(8), 1041-1049 (1995).
120. Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 47(1), 6-13 (1992).
121. Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect. Immun. 62(2), 596-605 (1994).
122. Anderson TR, Montie TC, Murphy MD, McCarthy VP. Pseudomonas aeruginosa flagellar antibodies in patients with cystic fibrosis. J. Clin. Microbiol. 27(12), 2789-2793 (1989).
123. Priebe GP, Dean CR, Zaidi TS et al. The galU gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect. Immun. 72(7), 4224-4232 (2004).
124. Krilov LR. Palivizumab in the prevention of respiratory syncytial virus disease. Expert Opin. Biol. Ther. 2(7), 763-769 (2002).
125. Lai Z, Kimmel R, Petersen S et al. Multivalent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal Pseudomonas sepsis caused by multiple serotypes. Vaccine 23(25), 3264-3271 (2005).
126. Yokota S, Terashima M, Chiba J, Noguchi H. Variable cross-reactivity of Pseudomonas aeruginosa lipopolysaccharide-core-specific monoclonal antibodies and its possible relationship with serotype. J. Gen. Microbiol. 138(FEB), 289-296 (1992).
127. Kohzuki T, Eguchi Y, Kato M et al. Protective activity of anti-exotoxin a monoclonal antibody against mice infected with toxin-producing Pseudomonas aeruginosa. J. Infect. Dis. 167(1), 119-125 (1993).